About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNCT06830759

Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lympho...

Lead sponsor: AbbVie•73 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Rebekah Taylor

CONTACT

(847) 937-8000 [email protected]

Sponsors

Lead Sponsor

AbbVie

Collaborators

Genmab

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Participants who are scheduled to be treated with epcoritamab for Treatment after two or more prior lines of therapy 3L+ diffuse large B-cell lymphoma ((D)LBCL) or 3L+ Follicular lymphoma (FL).
•Treatment with epcoritamab should be administered in accordance with the approved local label in the participating country.
•The decision to treat the participant should have been made by the clinician prior to, and independently of any decision to approach the participant to participate in this study.

Exclusion Criteria

•Any condition included in the contraindications section of the approved local epcoritamab label in the participating country.
•Participation in a concurrent interventional clinical trial (not including non-interventional/ observational study, PMOS, or registry participation) from enrollment and throughout the study.

Related studies

RECRUITINGPhase 1/2

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

NCT06395103 · B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, and more

RECRUITINGPhase 3

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma

RECRUITINGPhase 3

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

NCT06191744 · Follicular Lymphoma (FL)

An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma

NCT07200375 · Diffuse Large B-Cell Lymphoma

RECRUITINGPhase 2

Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma

NCT07545603 · Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 17, 2026Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment700

Start dateMar 2025

Last updatedFeb 17, 2026

Condition

Diffuse Large B-cell Lymphoma Follicular Lymphoma

Locations shown

Hospital Britanico de Buenos Aires /ID# 274419

Ciudad Autonoma de Buenos Aire, Buenos Aires

Hospital Universitario Austral /ID# 274393

Pilar, Buenos Aires

Instituto Alexander Fleming /ID# 277284

Ciudad Autonoma de Buenos Aire, Buenos Aires F.D.

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 17, 2026Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions